Effect of metformin therapy on vitamin D level in patients with type 2 diabetes mellitus
Journal Title: Міжнародний ендокринологічний журнал - Year 2019, Vol 15, Issue 2
Abstract
Background. Recent studies have shown that patients with diabetes mellitus (DM) often have skeletal disorders, in particular, reduced bone mineral density, osteoporosis. Apart from the disease itself, the nature of hypoglycemic therapy can make a significant contribution to increasing the risk of diabetes mellitus. The aim of the study was to evaluate the effect of metformin on the serum vitamin D level in patients with type 2 DM. Materials and methods. There were 47 patients under observation. The main group (n = 25) included patients who suffered from type 2 DM and received treatment with metformin, a hypoglycemic drug. The control group consisted of apparently healthy persons (n = 22). The study excludes patients with pathology of parathyroid glands, thyroid function disorders, kidney disease, and those taking vitamin D or calcium. Levels of 25-hydroxyvitamin D (25(OH)D), parathormone, ionized calcium, glycated hemoglobin (HbA1c) were evaluated. Results. Forty-seven patients aged 42 to 69 years (average age 58.0 ± 17.5 years) were examined. A study of serum 25(OH)D level showed that in most patients it was low. The average level of 25(OH)D in the main group was 18.37 ± 7.62 ng/ml (5.89–32.8 ng/ml). The study showed a higher prevalence of vitamin D deficiency among patients with type 2 DM (66.7 %) receiving metformin than in the control group (7.69 %). It was found that vitamin D levels were lower in patients with poorer glycemic control of type 2 DM (HbA1c > 7 %) — 15.03 ± 7.60 ng/ml and 22.75 ± 7.62 ng/ml, respectively. Conclusions. The study showed a higher prevalence of vitamin D deficiency among patients with type 2 DM (66.7 %) receiving metformin than in the control group (7.69 %). A reliable inverse correlation was found between the elevated HbA1c level and reduced 25(OH)D content. The level of 25(OH)D was significantly lower in the main group of patients receiving metformin therapy compared to the control group.
Authors and Affiliations
K. O. Masliy
Keywords
Related Articles
- EP ID EP605134
- DOI 10.22141/2224-0721.15.2.2019.166105
- Views 42
- Downloads 0
Orphan Hereditary Syndromes in the Practice of Pediatric Endocrinologist
The lecture presents short phenotypic and genetic characteristics of orphan endocrine syndromes associated with gigantism.
Autoimmune Disorders in Endocrine Pathology. A New Look on the Diagnosis and Management According to the Materials of 18th European Congress of Endocrinology (Munich, May 2016)
The paper presents the current data on the effect of the presence of autoantibodies on the management of autoimmune diseases: autoimmune thyroiditis, diabetes mellitus, states of carriage of antithyroid and diabetes-asso...
Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: laboratory criteria for the diagnosis and control of treatment efficacy
Non-classic congenital adrenal hyperplasia (NCAH) due to 21-hydroxylase deficiency is one of the actual causes of hyperandrogenic manifestations at different age intervals. Timely diagnosis of the disease requires evalua...
The Possibilities of Drug Prevention of Diabetes Mellitus Type 2
Over the past few years there have been several randomized controlled trials that examine the effect of lifestyle modification and pharmacological interventions on the likelihood of developing diabetes mellitus (DM) type...
Male factor of sterility: algorithm of laboratory diagnosis of the causes (part 2)
Previously, the topics of laboratory diagnosis were covered: assessment of the male androgenic status: what to choose — total or free testosterone; or use an estimated indicator — free testosterone index; what is importa...